公开(公告)号：US20210253554A1

公开(公告)日：2021-08-19

申请号：US17242428

申请日：2021-04-28

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Chunjian Liu ,  Michael G. Yang ,  Zili Xiao ,  Ling Chen ,  Ryan M. Moslin ,  John S. Tokarski ,  David S. Weinstein ,  Stephen T. Wrobleski

IPC分类号： C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14 ,  C07F9/6558 ,  C07D417/14 ,  A61P37/00 ,  A61P29/00 ,  A61K31/501 ,  C07D487/04

摘要： Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US11021462B2

公开(公告)日：2021-06-01

申请号：US16195951

申请日：2018-11-20

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Chunjian Liu ,  Michael G. Yang ,  Zili Xiao ,  Ling Chen ,  Ryan M. Moslin ,  John S. Tokarski ,  David S. Weinstein ,  Stephen T. Wrobleski

IPC分类号： A61K31/395 ,  C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14 ,  C07F9/6558 ,  C07D417/14 ,  A61P37/00 ,  A61P29/00 ,  A61K31/501 ,  C07D487/04

摘要： Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20200071315A1

公开(公告)日：2020-03-05

申请号：US16687279

申请日：2019-11-18

申请人： Bristol-Myers Squibb Company

发明人： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S. Tokarski ,  Amit Kumar ,  Douglas G. Batt ,  Shuqun Lin ,  Chunjian Liu ,  Steven H. Spergel ,  Yanlei Yanlei ,  Qingjie Liu

IPC分类号： C07D417/14 ,  C07B59/00 ,  C07D417/12 ,  C07D413/12 ,  C07D403/14 ,  C07D237/24 ,  C07D401/12 ,  C07D413/14 ,  C07D401/14 ,  C07D403/12

摘要： Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20180265504A1

公开(公告)日：2018-09-20

申请号：US15979770

申请日：2018-05-15

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S. Tokarski ,  Amit Kumar ,  Douglas G. Batt ,  Shuqun Lin ,  Chunjian Liu ,  Steven H. Spergel ,  Yanlei Zhang ,  Qingjie Liu

IPC分类号： C07D417/14 ,  C07B59/00 ,  C07D417/12 ,  C07D413/12 ,  C07D403/12 ,  C07D237/24 ,  C07D401/12 ,  C07D413/14 ,  C07D401/14 ,  C07D403/14

摘要： Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US10000480B2

公开(公告)日：2018-06-19

申请号：US15289437

申请日：2016-10-10

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S. Tokarski ,  Amit Kumar ,  Douglas G. Batt ,  Shuqun Lin ,  Chunjian Liu ,  Steven H. Spergel ,  Yanlei Zhang ,  Qingjie Liu

IPC分类号： C07D417/14 ,  C07D403/12 ,  C07D401/14 ,  C07D413/14 ,  C07D401/12 ,  C07D237/24 ,  C07D403/14 ,  C07D413/12 ,  C07D417/12 ,  C07B59/00

摘要： Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.